Holen Sie sich die Stockscreener-App
10.30
1.81%
-0.19
Handel nachbörslich:
10.50
0.20
+1.94%
Dbv Technologies Adr Aktie (DBVT) Neueste Nachrichten
European Stocks Shine As ADRs Climb Higher - Finimize
DBV Technologies’ SWOT analysis: peanut allergy patch stock poised for growth - Investing.com
DBV Technologies (NASDAQ:DBVT) Stock Price Crosses Above 50 Day Moving Average – Here’s Why - Defense World
DBV Technologies to Participate in Upcoming EAACI Congress 2025 - The Manila Times
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting - GlobeNewswire
DBV Technologies Secures Full Shareholder Support at Annual Meeting: Key Governance Updates - Stock Titan
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document - GlobeNewswire
DBV Technologies Reveals Special CEO Pay Package Ahead of Critical Shareholder Vote - Stock Titan
European ADRs Climb With Biotech Stocks Leading The Charge - Finimize
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
DBV Technologies (NASDAQ:DBVT) Raised to Sell at The Goldman Sachs Group - Defense World
Goldman Sachs cuts DBV Technologies stock to Sell, target EUR1.30 By Investing.com - Investing.com South Africa
Goldman Sachs cuts DBV Technologies stock to Sell, target EUR1.30 - Investing.com India
Goldman Sachs reinstates DBV Technologies with sell rating, $7.25 target By Investing.com - Investing.com India
Goldman Sachs reinstates DBV Technologies with sell rating, $7.25 target - Investing.com
DBV Technologies (NASDAQ:DBVT) Price Target Raised to $21.00 at JMP Securities - Defense World
European ADRs Rise On S&P Europe Select Index - Finimize
DBV Technologies’ SWOT analysis: peanut allergy treatment stock faces pivotal trial - Investing.com
European ADRs Show Optimism As Genfit Leads Gains - Finimize
European ADRs Slip As US Index Notes Mixed Gains And Losses - Finimize
Comparing DBV Technologies (NASDAQ:DBVT) and Maze Therapeutics (NASDAQ:MAZE) - Defense World
Are You Looking for a Top Momentum Pick? Why DBV Technologies S.A. (DBVT) is a Great Choice - Nasdaq
European ADRs Dip As Pharma And Tech Stocks See Mixed Results - Finimize
Combined General Meeting of June 11, 2025 - GlobeNewswire
DBV Technologies Sets Critical Shareholder Meeting: Key Documents Now Available - Stock Titan
European ADRs Show Modest Gains With Standout Performers - Finimize
StockNews.com Upgrades DBV Technologies (NASDAQ:DBVT) to “Hold” - Defense World
FY2025 EPS Forecast for DBV Technologies Boosted by Analyst - Defense World
European ADRs Dip With Mixed Performances Across Key Sectors - Finimize
What is HC Wainwright’s Estimate for DBVT Q2 Earnings? - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A.DBVT - Barchart.com
HC Wainwright Issues Positive Forecast for DBV Technologies (NASDAQ:DBVT) Stock Price - Defense World
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference - The Manila Times
DBV Technologies stock target raised to $16 by H.C. Wainwright - Investing.com Nigeria
DBV Technologies CEO Set for Key Presentation: How to Watch Live Fireside Chat at JMP Conference - Stock Titan
JMP Securities Boosts DBV Technologies (NASDAQ:DBVT) Price Target to $15.00 - Defense World
DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com - Defense World
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):